Virologic Tools for HCV Drug Resistance Testing

Recent advances in molecular biology have led to the development of new antiviral drugs that target specific steps of the Hepatitis C Virus (HCV) lifecycle. These drugs, collectively termed direct-acting antivirals (DAAs), include non-structural (NS) HCV protein inhibitors, NS3/4A protease inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Fourati, Slim, Pawlotsky, Jean-Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4690865/
https://www.ncbi.nlm.nih.gov/pubmed/26690198
http://dx.doi.org/10.3390/v7122941

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4690865/
https://www.ncbi.nlm.nih.gov/pubmed/26690198
http://dx.doi.org/10.3390/v7122941

Ejemplares similares